Read More Pharma Industry News AstraZeneca, Daiichi Sankyo score tenth BTD for Enhertu in early HER2 disease AstraZeneca and Daiichi Sankyo’s Enhertu earns FDA breakthrough tag in early breast cancer. Find out what this means for HER2 treatment strategy in 2025. byPallavi MadhirajuJanuary 2, 2026